Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
NCT ID: NCT00370747
Last Updated: 2013-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
162 participants
INTERVENTIONAL
2006-09-30
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
NCT00667004
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
NCT00198536
A Multi-Center Study Subjects With Dry Eye Syndrome
NCT01745887
Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease
NCT00758784
Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye
NCT00037661
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ecabet
Ophthalmic solution in the Study eye four times daily for 90 days.
Ecabet
ophthalmic solution 2.83%
Ecabet
ophthalmic solution 3.70%
Placebo
Ophthalmic solution in the Study eye four times daily for 90 days.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ecabet
ophthalmic solution 2.83%
Ecabet
ophthalmic solution 3.70%
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Agree to avoid disallowed medications
* Have a diagnosis of dry eye
Exclusion Criteria
* Have active seasonal ocular allergies
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bausch & Lomb Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ralph Bianca, PhD
Role: STUDY_DIRECTOR
ISTA Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Irvine, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ISTA-ECBT-CS02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.